Benralizumab
CD125 | |
|---|---|
| Clinical data | |
| Pronunciation | ben" ra liz' ue mab |
| Trade names | Fasenra |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618002 |
| License data |
|
| Pregnancy category |
|
Subcutaneous | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10060N1724O2028S42 |
| Molar mass | 146056.45 g·mol−1 |
  (what is this?) (verify) | |
Benralizumab, sold under the brand name Fasenra, is a
Two phase III clinical trials of benralizumab reported meeting their
eosinophilic oesophagitis in August 2019.[8]
Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.[9]
References
- ^ "Search Page - Drug and Health Product Register". 23 October 2014.
- ^ "Fasenra EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2020.
- USAN Council: Benralizumab
- PMID 20799138.
- ^ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
- PMID 28530840.
- ^ "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.
- ^ "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". www.astrazeneca.com. Retrieved 2019-10-29.
- ^ FDA Professional Drug Information
External links
- "Benralizumab". Drug Information Portal. U.S. National Library of Medicine.